A number of research firms have changed their ratings and price targets for Abivax (NASDAQ: ABVX):
- 6/16/2026 – Abivax had its “buy” rating reaffirmed by BTIG Research. They now have a $150.00 price target on the stock.
- 6/3/2026 – Abivax was given a new $136.00 price target by Wolfe Research.
- 6/3/2026 – Abivax had its “outperform” rating reaffirmed by Wolfe Research.
- 6/2/2026 – Abivax had its price target lowered by Truist Financial Corporation from $140.00 to $135.00. They now have a “buy” rating on the stock.
- 6/2/2026 – Abivax had its price target lowered by Morgan Stanley from $145.00 to $132.00. They now have an “overweight” rating on the stock.
- 6/2/2026 – Abivax had its “outperform” rating reaffirmed by Citigroup Inc..
- 6/2/2026 – Abivax was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $90.00 price target on the stock, down from $160.00.
- 6/2/2026 – Abivax had its price target raised by Citizens Jmp from $131.00 to $187.00. They now have a “market outperform” rating on the stock.
- 6/2/2026 – Abivax was upgraded by Wedbush from “underperform” to “neutral”. They now have a $90.00 price target on the stock, down from $110.00.
- 6/2/2026 – Abivax had its “buy” rating reaffirmed by BTIG Research. They now have a $150.00 price target on the stock.
- 5/26/2026 – Abivax had its “market outperform” rating reaffirmed by Citigroup Inc..
- 5/26/2026 – Abivax had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $131.00 price target on the stock.
- 5/23/2026 – Abivax was upgraded by Wall Street Zen from “sell” to “hold”.
- 4/26/2026 – Abivax was downgraded by Wall Street Zen from “hold” to “sell”.
Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.
Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.
Featured Stories
- Five stocks we like better than Abivax
- Top Consumer Discretionary Brands Add Buyback Capacity Amid Weakness
- Micron’s Sudden Plunge May Be an AI Buying Chance
- As Inflation Hits 3-Year High, These 2 ETFs Are Designed to Hedge Against Rising Costs
- BitMine’s Ethereum Bet Is Only Part of the Story
Receive News & Ratings for Abivax SA Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax SA Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
